XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Agenus (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Feb. 28, 2017
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
License Agreements        
Fair market long term investments   $ 128,313   $ 133,676 [1]
Unrealized gain (loss) on long term investments   $ (5,318) $ (46,585)  
Agenus        
License Agreements        
Common stock held from investment (in shares)   12,100,000    
Fair market long term investments   $ 18,300   $ 29,000
Unrealized gain (loss) on long term investments   (10,600) $ (9,200)  
Agenus        
License Agreements        
Period of notice for termination of license agreement 12 months      
Agenus | Development, Regulatory and Commercialization Milestones        
License Agreements        
Milestone payment made under license agreement   30,000    
Additional milestone payments under the license agreement   $ 500,000    
Royalty-bearing product other than GITR, OX40 and one undisclosed target | Minimum | Agenus        
License Agreements        
Royalty payments on future global net sales (as a percent) 6.00%      
Royalty-bearing product other than GITR, OX40 and one undisclosed target | Maximum | Agenus        
License Agreements        
Royalty payments on future global net sales (as a percent) 12.00%      
Royalty-bearing product GITR, OX40 and one undisclosed target | Maximum | Agenus        
License Agreements        
Royalty payments on future global net sales (as a percent) 15.00%      
[1] The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date.